Study Information

Alliance Study ID: CALGB-30605

NCT Study ID (ClinicalTrials.gov): NCT00553462

Alliance Committee: Respiratory Cancer

Disease or Cancer Type: Lung Cancer & Mesothelioma

Alliance Study Chair: Rogerio Lilenbaum, MD

Status: COMPLETED


Study Description

RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Erlotinib may make tumor cells more sensitive to radiation therapy. Giving carboplatin and paclitaxel albumin-stabilized nanoparticle formulation together with radiation therapy and erlotinib may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving carboplatin and paclitaxel albumin-stabilized nanoparticle formulation together with radiation therapy and erlotinib works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery.

Related Publications

For publications related to this and other clinical trials, visit the Alliance Publications Application.

Data Sources & Contacts

Related Alliance Trials